Celularity Inc. Net Income (Loss) Attributable to Redeemable Noncontrolling Interest
Celularity Inc. (CELU) reported Net Income (Loss) Attributable to Redeemable Noncontrolling Interest of -$50.26 million for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-05-24.
Discontinued › Income Statement
us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest · last filed 2021-05-24
- Celularity Inc. net income (loss) attributable to redeemable noncontrolling interest for fiscal 2020 was -$50.26M, a 1614.52% decline from fiscal 2019.
- Celularity Inc. net income (loss) attributable to redeemable noncontrolling interest for fiscal 2019 was $3.32M.
| Period end | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 12 month |
|---|---|
| 2020-12-31 | -$50.26M 10-K/A · filed 2021-05-24 |
| 2019-12-31 | $3.32M 10-K/A · filed 2021-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |